GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Profitability Rank

Sumitomo Pharma Co (Sumitomo Pharma Co) Profitability Rank

: 6 (As of Dec. 2023)
View and export this data going back to 2009. Start your Free Trial

Sumitomo Pharma Co has the Profitability Rank of 6.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Sumitomo Pharma Co's Operating Margin % for the quarter that ended in Dec. 2023 was -37.93%. As of today, Sumitomo Pharma Co's Piotroski F-Score is 2.


Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co Profitability Rank Distribution

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Profitability Rank falls into.



Sumitomo Pharma Co Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Sumitomo Pharma Co has the Profitability Rank of 6.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Sumitomo Pharma Co's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-217.021 / 572.199
=-37.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Sumitomo Pharma Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Sumitomo Pharma Co Profitability Rank Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.